HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Lehman, R. Search for Related Content PubMed Articles by Lehman, R. Topic Collections EBM Notebook

Evidently...

Department of Primary Care, University of Oxford
Oxford, UK

The first 150 words of the full text of this article appear below.

Before the coming of standardised European road signs, roads that led nowhere in England used to be marked "No Through Road" or "Cul-de-Sac," if they were marked at all. Unfortunately, there is no similar system to guide interventional trials of cardiovascular prevention. When researchers repeatedly go up a certain promising path and end up getting nowhere, others often still follow. Raising high density lipid cholesterol (HDL-C) is an example: observational data show that high levels are associated with fewer adverse cardiovascular outcomes, but no trial seems to arrive at that destination. Earlier trials used fibrates, but the latest have used new classes of HDL-C raising drugs: a peroxisome-activated receptor- called LY18674, which proved such a failure that it will probably never get a name ( JAMA 2007;297:1362–73[Abstract/Free Full Text] ), and an inhibitor of cholesteryl ester transferase, torcetrapib. Combined with a statin, this agent raised HDL-C . . . [Full text of this article]